1. Barthel H, Cleij MC, Collingridge DR et al. (2003) 3_-deoxy-3_-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63: 3791–3798
2. Beer AJ, Haubner R, Goebel M et al. (2005) Biodistribution and pharmacokinetics of the αvβ3 selective tracer 18F Galacto-RGD in cancer patients. J Nucl Med 46: 1333–1341
3. Beer AJ, Haubner R, Wolf I et al. (2006) PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 47: 763–769
4. Beer AJ, Wieder HA, Lordick F et al. (2006) Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology 239: 472–480
5. Beer AJ, Haubner R, Sarbia M et al. (2006) Positron emission tomography using [18F]galacto-RGD identifies the level of integrin αvβ3 expression in man. Clin Cancer Res 12: 3942–3949